Peer-Reviewed Publications

A growing body of evidence supports the potential of resmetirom for the treatment of patients with NASH with significant fibrosis.

  • Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin MC, Tardif JC. Atherosclerosis. 2013 Oct;230(2):373-80. DOI: 1016/j.atherosclerosis.2013.07.056.
  • Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, So SS, Thakkar K, Qian Y, Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J. J Med Chem. 2014 May 22;57(10):3912-23. DOI: 1021/jm4019299.
  • Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Lancet. 2019 Nov 30;394(10213):2012-2024. DOI: 1016/S0140-6736(19)32517-6.
  • Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Hepatol Commun. 2021 Jan 4;5(4):573-588. DOI: 1002/hep4.1657.
  • Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Clin Gastroenterol Hepatol. 2021 Jul 27:S1542-3565(21)00821-1. DOI: 1016/j.cgh.2021.07.039.

NASH is a growing global health challenge. There are 22 million people living with NASH in the U.S. alone, and more than 8 million who have NASH with significant liver fibrosis.